Sandra Tejedor Gascòn

Title: Sandra Tejedor Gascòn: Innovator in Cardiotoxicity Prediction

Introduction

Sandra Tejedor Gascòn is a prominent inventor based in Valencia, Spain. She has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. Her innovative approach utilizes a combination of circulating microRNAs as biomarkers for this critical health issue.

Latest Patents

Sandra holds a patent for her invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention outlines an in vitro method for assessing the risk of cardiotoxicity by determining the expression levels of a specific set of 10 circulating miRNAs in biological samples from patients. The identified miRNAs include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. This invention not only serves as a predictive biomarker but also proposes a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.

Career Highlights

Throughout her career, Sandra has worked with notable institutions, including the Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana and Maastricht University. Her work has been instrumental in advancing the understanding of cardiotoxicity in cancer treatment.

Collaborations

Sandra has collaborated with esteemed colleagues such as David Hervàs Marin and Ana Santaballa Beltràn. These partnerships have further enriched her research and contributed to the development of her innovative solutions.

Conclusion

Sandra Tejedor Gascòn is a trailblazer in the field of cardiotoxicity prediction, with her patent representing a significant advancement in cancer patient care. Her work exemplifies the impact of innovative research on improving health outcomes for vulnerable populations.